Sigma-Aldrich Corp

Sigma-Aldrich — Investor Presentation (January 2013)

24 slides from Sigma-Aldrich's investor presentation, Jan 7, 2013

  1. Slide 1: Sigma-Aldrich Corporation Investor Information January 2013

    © 2012 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich Corporation January 2013 Investor Information

  2. Slide 2: Cautionary Statements

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 2 Cautionary Statements • This presentation contains “forward-looking statements” regarding future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other

  3. Slide 3: Sigma-Aldrich Overview: Delivering Value Through A Diversified Portfolio

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich Overview 3 Delivering Value Through A Diversified Portfolio No customer comprises more than 2% of sales, no product more than 1% GLOBALLY BALANCED 40% United States and Canada 37% Europe, Middle East, Africa 23% Asia Pacific and Latin

  4. Slide 4: History of the Company

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. History of the Company 37 Consecutive Years of Increasing EPS and Annual Dividends 4

  5. Slide 5: Progression of Research vs SAFC

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 5 Progression of Research vs SAFC 90% 10% 1990 SAFC Research 2000 2010 2012 (YTD Q3) 85% 15% 72% 28% 68% 32% $0.5 Billion Sales 51,000 Products 4,100 Employees $1.1 Billion Sales 85,000 Products 6,200 Employees $2.3 Billion Sales 187,000 Products 7,

  6. Slide 6: Business Units Driven by Product-Centric Lens

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Business Units Were Driven by Focus through a Product-Centric Lens – ABCM 6 2012 (YTD Q3) RESEARCH BUSINESS PRODUCT SEGMENTS Analytical Biology Chemistry Materials Science 68% 32% Note: percentages comprise approximate size of business to total comp

  7. Slide 7: Driving Our Products into a Variety of Customer Classes

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. We Have Been Successful in Driving Our Products into a Variety of Customer Classes 7 Academic & Government Researchers Pharma & Biotech Discovery R&D Contract Research Organizations Dealers Clinical Laboratories Testing Labs Environmental Labs Indus

  8. Slide 8: Enhancing Focus through a Customer-Centric Lens

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. APPLIED & INDUSTRIAL MARKETS COMMERCIAL MARKETS RESEARCH MARKETS Enhancing Focus through a Customer-Centric Lens 8 Academic & Government Researchers Pharma & Biotech Discovery R&D Contract Research Organizations Dealers Clinical Laboratories Testing

  9. Slide 9: Creation of Customer-Focused Business Units

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Creation of Customer-Focused Business Units (BU) 9 Life Science BioReliance Hitech Diagnostics & Testing Labs Industrial Customers Pharmaceutical Academic & Government Dealers CURRENT Product-focused Organization RESEARCH ABCM (All Research Products

  10. Slide 10: Business Units and Market Outlook

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Business Units and Market Outlook 10 RESEARCH APPLIED & INDUSTRIAL COMMERCIAL Sigma-Aldrich Mission Approx % of Total Sales Long-term Market Growth Outlook Broad supplier of products to the research laboratory 50% Low-to-mid single digits Supplier o

  11. Slide 11: Research Markets

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 11 Description Reagents and consumables to life sciences and non-profit research organizations Manufacturing raw materials for commercial products Raw materials and solutions for testing in clinical and industrial applications Customer Market Segmen

  12. Slide 12: Research Business Unit

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. RESEARCH Business Unit 12 Academic & Government Pharma & Biotech Discovery Dealers INITIATIVES CUSTOMER FOCUS • Continue to broaden product portfolio • Broaden/deepen our sales channels - eCommerce - Direct sales - Dealers • Work closer with major c

  13. Slide 13: SAFC Commercial Markets

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 13 Description Reagents and consumables to life sciences and non-profit research organizations Manufacturing raw materials for commercial products Raw materials and solutions for testing in clinical and industrial applications Customer Market Segmen

  14. Slide 14: Commercial Business Unit

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. COMMERCIAL Business Unit 14 Commercial Pharma & Biotech Electronics Services INITIATIVES CUSTOMER FOCUS • SAFC Top-100 Customer Strategy • Strengthen our leading position in cell culture media • Leverage our High Potency Compound (HPC) capacity • Br

  15. Slide 15: Applied & Industrial Markets

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 15 Description Reagents and consumables to life sciences and non-profit research organizations Manufacturing raw materials for commercial products Raw materials and solutions for testing in clinical and industrial applications Customer Market Segmen

  16. Slide 16: Applied & Industrial Business Unit

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. APPLIED & INDUSTRIAL Business Unit 16 Clinical Diagnostics Environmental Labs Industrial MOVING UP THE VALUE CHAIN CUSTOMER FOCUS COMPONENTS • Antibodies • Lab Essentials • Standards • Sample Prep • Oligos • Enzymes • LC/GC Columns • Solvents • Buff

  17. Slide 17: 2012 Q3 YTD Organic Sales Growth

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 2012 Q3 YTD Organic Sales Growth 17 RESEARCH ABCM (All Research Products) SAFC (All Commercial Products) 2% COMMERCIAL APPLIED & INDUSTRIAL RESEARCH 1% 4% 5% TOTAL 3% Product-focused Organization Customer-focused Organization 5% TOTAL 3%

  18. Slide 18: 2012 Guidance

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 2012 Guidance* Organic Sales Growth 18 Guidance for full-year adjusted EPS to be $3.80-3.90 * Outlook provided on 10/23/12 1st Half 2nd Half Full Year Research Low Single-digit Low Single-digit ~3% SAFC Mid Single-digit Mid-to-High Single-digit • Ch

  19. Slide 19: Key Considerations for 2013

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Key Considerations for 2013 19 Positioning for continued growth in 2013 • Macro-economic environment • Pharma consolidation / site closures • Increased presence in Applied & Industrial Markets • SAFC Growth • Emerging Market Growth • Capital deploym

  20. Slide 20: Proven Formula for Value Creation

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 22.4 22.5 22.9 23.2 24.3 25.7 2006 2011 1 ,7 9 8 2 ,0 3 9 2 ,2 0 1 2 ,1 4 8 2 ,2 7 1 2 ,5 0 5 2006 2011 Proven Formula for Value Creation +7% +340bps +10bps CAGR 20 20.9 20.6 22.8 22.8 21.5 21% 2006 2011 SALES GROWTH STRONG ROE GAAP MARGIN EXPANSION

  21. Slide 21: Why Sigma-Aldrich?

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Why Sigma-Aldrich? 21 STRONG FINANCIAL POSITION PROVEN GLOBAL FRANCHISE - Well Diversified - Recognized Brands - Established Markets - Operational Excellence - Efficient Supply Chain Management FOCUSED STRATEGIES FOR GROWTH - Innovative Platforms -

  22. Slide 22: Questions?

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. QUESTIONS? 22

  23. Slide 23: Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. 23 Appendix Reconciliation of GAAP to Non-GAAP Financial Measures

  24. Slide 24: Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth

    © 2013 Sigma-Aldrich Co. LLC. All rights reserved. Acquisition Adjusted Reported Currency Benefit (Organic) Research Chemicals (4)% (6)% 1% 1% SAFC 17% (5)% 17% 5% 2% (6)% 6% 2% Acquisition Adjusted Reported Currency Benefit (Organic) Research Chemicals (1)% (4)% 1% 2% SAFC 16% (4)% 15% 5% Total Cus

Sigma-Aldrich — Investor Presentation (January 2013) on 6ix